OASYS NOW and Progress Clinical Research Join Forces to Accelerate Clinical Drug Trials in The Netherlands

December 16th, 2024 – In a groundbreaking collaboration, OASYS NOW, a pioneering AI and cybersecurity firm specializing in healthcare and life sciences, and winner of the Slush 100 competition, has partnered with Progress Clinical Research, a leading clinical trial site company in the Netherlands, previously awarded as IQVIA Prime Site. This partnership leverages OASYS NOW’s cutting-edge AI-powered solution, ELaiGIBLE, to revolutionize the patient recruitment process for clinical trials.

Progress Clinical Research, along with its Brain Research Center brand, established in 2009 from the Amsterdam UMC, operates trial sites in Amsterdam, Den Bosch, and Zwolle. They connect patients, pharmaceutical companies, biotech firms, and healthcare professionals. Their mission is to make significant contributions to the registration of innovative drugs targeting central nervous system, cardiometabolic, and immune diseases. By focusing on these areas, they aim to improve the quality of life for patients with unmet medical needs, offering hope and new treatment options.

OASYS NOW‘s mission to make personalized health accessible and equitable aligns perfectly with Progress Clinical Research’s vision. ELaiGIBLE, an AI copilot for eligibility screening, streamlines the identification of potential clinical trial candidates from electronic health records. By automating the extraction and categorization of eligibility criteria from clinical trial protocols, ELaiGIBLE significantly reduces the time and resources required for patient pre-screening.

“This collaboration marks a significant step forward in our mission to increase health through accelerating the development of breakthrough treatments for a range of diseases where there is a high unmet need for patients,” says Niels Prins, CEO of Progress Clinical Research. “ELaiGIBLE’s ability to efficiently identify eligible patients will empower us to expedite our clinical trials and bring new hope to patients and their families.”

ELaiGIBLE acts as an AI assistant, providing clinicians with a prioritized list of potential candidates, complete with matching scores and supporting documentation. This not only enhances the efficiency of patient prescreening and recruitment, but also ensures that the most suitable candidates are identified, leading to less screen failures and more successful clinical trials.

“Our collaboration with Progress Clinical Research is a significant step towards a future where personalized medicine is a reality for everyone. By streamlining clinical trials and accelerating research, we’re paving the way for more targeted and effective treatments for a variety of diseases.” says Nima Salami, CEO & Co-Founder of OASYS NOW. “We are confident that our collaboration with Progress Clinical Research will have a profound impact on the lives of patients and contribute to a future where diseases are no longer a threat.”

The partnership between OASYS NOW and Progress Clinical Research exemplifies the transformative power of AI in healthcare. By combining their expertise and resources, these two organizations are paving the way for a future where clinical trials are more efficient, effective, and accessible to all.

About OASYS NOW:

OASYS NOW is a pioneering AI and Cybersecurity provider in Life Science and Healthcare, committed to making personalized health accessible and equitable to everyone globally. Their innovative solutions empower healthcare organizations to improve patient outcomes and accelerate research.

About Progress Clinical Research:

Progress Clinical Research, along with its Brain Research Center brand, stands as a premier clinical trial site company in the Netherlands. Specializing in central nervous system, cardiometabolic, and immune diseases, they are committed to bridging the gap between patients, pharmaceutical and biotech companies, and medical specialists. Their mission is to discover groundbreaking treatments for patients with unmet medical needs.

Contact:

Nima Salami, CEO & Co-Founder, OASYS NOW
nima@oasysnow.com

Niels Prins, CEO & Co-Founder, Progress Clinical Research
n.prins@brainresearchcenter.nl